Pediatric poisoning from trimedoxime (TMB4) and atropine automatic injectors - 15/08/11
, Amnon Mordel, MD, Shmuael Bar Haim, MD, Mordechei Bulkowstein, MD, Matitiahu Berkovitch, MD, Yedidia Bentur, MD
Reprint requests: Eran Kozer, MD, Assaf Harofeh Medical Center, Pediatric Emergency Services, Zerifin 70300, Israel.See editorial, p 8.
Abstract |
Objective |
To describe the effects of combined trimedoxime (TMB4) and atropine poisoning from automatic injectors (AI) in children.
Study design |
Data was collected from two sources: calls to the Israel Poison Information Center (IPIC) during a 1-year period and a cohort of children who presented to pediatric emergency departments (EDs) after unintentional injection of an AI. Demographic data and data regarding the type of AI, site and time of injection, and the clinical manifestations were abstracted.
Results |
Data were available for 142 patients. The median age was 8.5 years (range 1.25-18 years). The dose of atropine and TMB4 was higher than the recommended dose for age in 22 (15.5%) cases. There were few side effects attributable to atropine: dilated pupils (26.7%), dryness of mucous membranes (24.6%), and tachycardia (22.5%). Compared with children injected with an age-appropriate dose, children injected with an AI that contained a dose that exceeds the recommended one were more likely to be symptomatic (P=.029). There were no side effects characteristic to oximes, and no specific medical intervention was required.
Conclusions |
Unintentional pediatric atropine and TMB4 injection, even an adult dose in a small child, does not cause significant side effects.
Le texte complet de cet article est disponible en PDF.Mots-clés : AI, ED, IPIC, TMB4
Plan
| Presented in part at the North American Congress of Clinical Toxicology, Chicago, Illinois, September 2003, and at the second Mediterranean Emergency Medicine Congress, Sitges/Barcelona, Spain, September 2003. |
Vol 146 - N° 1
P. 41-44 - janvier 2005 Retour au numéro
Article précédent
- Children with early-onset inflammatory bowel disease (IBD): Analysis of a pediatric IBD consortium registry
- Melvin B. Heyman, Barbara S. Kirschner, Benjamin D. Gold, George Ferry, Robert Baldassano, Stanley A. Cohen, Harland S. Winter, Patricia Fain, Chris King, Terry Smith, Hashem B. El-Serag
- Growth hormone (GH) treatment to final height in children with idiopathic short stature: Evidence for a dose effect
- Jan M. Wit, Lyset T.M. Rekers-Mombarg, Gordon B. Cutler, Brenda Crowe, Tracy J. Beck, Kristen Roberts, Anne Gill, Jean-Louis Chaussain, Herwig Frisch, Rafael Yturriaga, Andrea F. Attanasio, on Behalf of the European Idiopathic Short Stature Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?